Effect of fluoxetine on dexamethasone-induced growth hormone release in depression: a double-blind, placebo-controlled study.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

The authors' objective was to characterize the effects of fluoxetine treatment on dexamethasone-induced growth hormone (GH) responses in depressed patients.

Who Took Part

PubMed indexes the participants as adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

What Was Measured

PubMed files the paper under topics including Ambulatory Care, Depressive Disorder, Dexamethasone, Fluoxetine, Growth Hormone and Psychiatric Status Rating Scales.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 2 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1995 (The American journal of psychiatry), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.